<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571515</url>
  </required_header>
  <id_info>
    <org_study_id>MECC-TBZ-2001</org_study_id>
    <nct_id>NCT04571515</nct_id>
  </id_info>
  <brief_title>Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Parallel Group, Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MR-107A-01 is being studied to investigate its efficacy, safety, and dose-response after&#xD;
      dental surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2020</start_date>
  <completion_date type="Actual">December 22, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall summed pain intensity difference (SPID)</measure>
    <time_frame>24 hours after the first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Using a Numeric Pain Rating Scale</measure>
    <time_frame>24 hours after the first dose</time_frame>
    <description>10 point scale, where 0 is no pain and 10 is the worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Using a Numeric Scale</measure>
    <time_frame>24 hours after the first dose</time_frame>
    <description>5 point scale, where 0 is poor, 1 is fair, 2 is good, 3 is very good, and 4 is excellent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pain Relief</measure>
    <time_frame>24 hours after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment of Pain Control</measure>
    <time_frame>24 hours after the first dose</time_frame>
    <description>5 point scale, where 0 is poor, 1 is fair, 2 is good, 3 is very good, and 4 is excellent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use</measure>
    <time_frame>24 hours after the first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Pain</condition>
  <condition>Postoperative Pain</condition>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>MR-107A-01 15 mg once in a 24-hour period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet one day of dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MR-107A-01 10 mg once in a 24-hour period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet one day of dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MR-107A-01 15 mg twice in a 24-hour period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet one day of dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MR-107A-01 10 mg twice in a 24-hour period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet one day of dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo twice in a 24-hour period</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet one day of dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR-107A-01</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>MR-107A-01 10 mg once in a 24-hour period</arm_group_label>
    <arm_group_label>MR-107A-01 10 mg twice in a 24-hour period</arm_group_label>
    <arm_group_label>MR-107A-01 15 mg once in a 24-hour period</arm_group_label>
    <arm_group_label>MR-107A-01 15 mg twice in a 24-hour period</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Placebo twice in a 24-hour period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females ≥18 years of age.&#xD;
&#xD;
          2. Requirement for dental surgery for extraction of ≥2 x third molars, at least 1 of&#xD;
             which involves partial or complete mandibular bony impaction.&#xD;
&#xD;
          3. Pain Intensity (PI) using a Numeric Pain Rating Scale (NPRS) ≥5 during the 5 hours&#xD;
             following the end of surgery.&#xD;
&#xD;
          4. Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e.,&#xD;
             none, mild, moderate, severe) during the 5 hours following the end of surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously dosed with MR-107A-01.&#xD;
&#xD;
          2. Subject with known hypersensitivity to nonsteroidal antiinflammatory drugs (NSAIDs).&#xD;
&#xD;
          3. Active GI bleeding or a history of peptic ulcer disease, active inflammatory bowel&#xD;
             disease, e.g., Crohn's Disease or ulcerative colitis, bleeding disorders that may&#xD;
             affect coagulation.&#xD;
&#xD;
          4. Use of any investigational drug within 28 days, or 5 half-lives, prior to screening&#xD;
             whichever is longer.&#xD;
&#xD;
          5. Use of medications with the potential to interact with MR-107A-01.&#xD;
&#xD;
          6. Other acute or chronic medical or psychiatric condition or laboratory abnormality that&#xD;
             may increase the risk associated with study participation or investigational product&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the subject inappropriate for entry into this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Allan</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility 101</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

